Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

Journal of Clinical Oncology

Volumn 28, Issue 3, 2010, Pages 509-518

  Dowsett, Mitch ^a   Cuzick, Jack ^a   Ingle, Jim ^a   Coates, Alan ^a   Forbes, John ^a   Bliss, Judith ^a   Buyse, Marc ^a   Baum, Michael ^a   Buzdar, Aman ^a   Colleoni, Marco ^a   Coombes, Charles ^a   Snowdon, Claire ^a   Gnant, Michael ^a   Jakesz, Raimund ^a   Kaufmann, Manfred ^a   Boccardo, Francesco ^a   Godwin, Jon ^a   Davies, Christina ^a   Peto, Richard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; GOSERELIN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; HORMONAL THERAPY; HUMAN; LOG RANK TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; SYSTEMATIC REVIEW; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; FEMALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN;

EID: 75749092296     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.1274     Document Type: Article

References (21)

1. Jordan VC: The science of selective estrogen receptor modulators: Concept to clinical practice. Clin Cancer Res 12:5010-5013, 2006
2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomised trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
4. Dowsett M, Howell A: Breast cancer: Aromatase inhibitors take on tamoxifen. Nat Med 8:1341-1344, 2002
5. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442, 2003
6. Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial - Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Lancet Oncol 9:45-53, 2008
7. Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007
8. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005
9. Boccardo F, Rubagotti A, Guglielmini P, et al: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol 17:vii10-vii14, 2006 (suppl 7)
10. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
11. Cuzick J: Forest plots and the interpretation of subgroups. Lancet 365:1308, 2005
12. Early Breast Cancer Trialists' Collaborative Group: Treatment of Early Breast Cancer. Volume 1: Worldwide Evidence, 1985-1990. Oxford, United Kingdom, Oxford University Press, 1990
13. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757, 2002
14. Geisler J, King N, Anker G, et al: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089-2093, 1998
15. Mouridsen HT, Giobbie-Hurder A, Goldhirsch A, et al: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N ENgl J Med 36:766-776, 2009. Cancer Res 69:66s, 2009 (suppl)
16. Gutierrez MC, Detre S, Johnston S, et al: Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469-2476, 2005
17. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007
18. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
19. Cuzick J: Primary end-points for randomized trials of cancer therapy. Lancet 371:2156-2158, 2008
20. Lin NU, Winer EP: Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26:798-805, 2008
21. Lønning PE, Geisler J: Indications and limitations of third-generation aromatase inhibitors. Expert Opin Investig Drugs 17:723-739, 2008